2C-T-13

2C-T-13
Clinical data
Other names4-(2-Methoxyethylthio)-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-(2-methoxyethylthio)phenethylamine
Routes of
administration		Oral[1]
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Onset of action0.5 hours[1]
Peak: 1.0–1.5 hours[1]
Duration of action6–8 hours[1]
Identifiers
  • 2-{2,5-dimethoxy-4-[(2-methoxyethyl)sulfanyl]phenyl}ethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H21NO3S
Molar mass271.38 g·mol−1
3D model (JSmol)
  • COc1cc(SCCOC)c(cc1CCN)OC
  • InChI=1S/C13H21NO3S/c1-15-6-7-18-13-9-11(16-2)10(4-5-14)8-12(13)17-3/h8-9H,4-7,14H2,1-3H3 Y
  • Key:PYJLRNOGMKMRTK-UHFFFAOYSA-N Y
 NY (what is this?)  (verify)

2C-T-13, also known as 4-(2-methoxyethylthio)-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and 2C families.[1]

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 2C-T-13's dose as 25 to 40 mg orally and its duration as 6 to 8 hours.[1] The onset is 0.5 hours and time to peak is about 1 to 1.5 hours.[1]

The effects of 2C-T-13 have been reported to include closed-eye visuals such as colored visuals, patterns, and geometric shapes, open-eye visuals such as color changes, auditory changes like feeling like radio sounds are coming from outside, touches of introspection, insights or personal development such as deciding to quit smoking, no mental confusion, lightheadedness, slight dizziness, nausea, stomach discomfort, diarrhea, and no appetite loss.[1]

Interactions

See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Chemistry

2C-T-13 has structural properties similar to mescaline and other drugs in the 2C-T series, with the most closely related compounds being 2C-T-7 and 2C-T-21.[1]

Synthesis

The chemical synthesis of 2C-T-13 has been described.[1]

History

2C-T-13 was first described in the scientific literature by Alexander Shulgin and colleagues in 1991.[2] Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).[1]

Society and culture

Canada

As of October 31, 2016, 2C-T-13 is a controlled substance (Schedule III) in Canada.[3]

United States

2C-T-13 is not scheduled in the United States, but possession and sales of 2C-T-13 could be prosecuted under the Federal Analog Act because of its structural similarities to 2C-T-7.

See also

References

  1. ^ a b c d e f g h i j k Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. [1]
  2. ^ Shulgin AT, Shulgin A, Jacob P (January 1991). "Central nervous system (CNS) activity of two new psychoactive compounds". Journal of Psychoactive Drugs. 23 (1): 95–96. doi:10.1080/02791072.1991.10472583. eISSN 2159-9777. PMID 1941371. Archived from the original on 2025-07-13.
  3. ^ "Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". 4 May 2016.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.